why choose us

First received: August 12, 2022

Clinical Trial: Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Condition: Relapsed or Refractory Multiple Myeloma

Study Type: Expanded Access


Official Title: Pre-Approval Access Single Patient Request Treatment for Talquetamab for Treating Physician Use in Relapsed or Refractory Multiple Myeloma

Brief Summary: The purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.

Read more